(E)-2-(2-(2-methoxyethoxy)ethoxy)ethyl 2-cyano-3-(2-(4-methylpiperazin-1-yl) napthalen-6-yl)acrylate | 1290035-75-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-2-(2-(2-methoxyethoxy)ethoxy)ethyl 2-cyano-3-(2-(4-methylpiperazin-1-yl) napthalen-6-yl)acrylate
• 英文别名: 2-[2-(2-methoxyethoxy)ethoxy]ethyl (E)-2-cyano-3-[6-(4-methylpiperazin-1-yl)naphthalen-2-yl]prop-2-enoate
• CAS: 1290035-75-4
• 化学式: C₂₆H₃₃N₃O₅
• 分子量: 467.565
• InChiKey: VMCGTMUWVWWXNJ-HKOYGPOVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  34
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  84.3
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6-溴-2-萘甲醇 在 哌啶 、 三叔丁基膦 、 palladium diacetate 、 caesium carbonate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 98.0h， 生成 (E)-2-(2-(2-methoxyethoxy)ethoxy)ethyl 2-cyano-3-(2-(4-methylpiperazin-1-yl) napthalen-6-yl)acrylate
  参考文献：
  名称：

  Aminonaphthalene 2-Cyanoacrylate (ANCA) Probes Fluorescently Discriminate between Amyloid-β and Prion Plaques in Brain

  摘要：

  A major challenge for diagnosing and monitoring the progression of amyloid-based diseases is the capability to distinguish between amyloid deposits that are associated with related, but distinctly different, diseases. Here, we demonstrate that aminonaphthalenyl 2-cyanoacrylate-based probes can fluorescently discriminate between different types of amyloid deposits in brain. The discriminating capability of these molecular rotors is due to the stabilization of the ground versus excited states of these probes as a function of the polarity of their microenvironment (i.e., within the binding pocket on the amyloid). This property makes it possible, for the first time, to estimate the inherent static relative permittivity (epsilon(0)) of the binding pocket of each amyloid within tissue. The capability to selectively follow the deposition of specific amyloids in tissue may provide important information for therapeutic development that is not readily accessible from currently available technology.

  DOI：

  10.1021/ja3063698

文献信息

• COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY
  申请人：Amydis, Inc.

  公开号：US20210369873A1

  公开（公告）日：2021-12-02

  The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

  本公开涉及一般用于确定患者是否患有创伤性脑损伤（TBI）的组合物和方法，通过检测患者眼睛中淀粉样蛋白的存在。还提供了用于为创伤性脑损伤（TBI）的诊断和治疗准备患者的组合物和方法。
• HCV POLYMERASE INHIBITORS
  申请人：MEDIVIR AB

  公开号：US20150175648A1

  公开（公告）日：2015-06-25

  The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

  该发明提供了以下式子的化合物：其中B是从(a)到(d)组中选择的核苷碱：其他变量如权利要求中所定义，这些化合物可用于治疗或预防丙型肝炎病毒感染及相关方面。
• AMYLOID BINDING AGENTS
  申请人：The Regents of the University of California

  公开号：US20150177262A1

  公开（公告）日：2015-06-25

  There are provided compounds and methods for the detection of amyloids and treatment of diseases related to amyloids including Alzheimer's disease and other related amyloid-based neurodegenerative diseases.

  提供了化合物和方法，用于检测淀粉样蛋白和治疗与淀粉样蛋白相关的疾病，包括阿尔茨海默病和其他相关的淀粉样蛋白相关神经退行性疾病。
• HCV polymerase inhibitors
  申请人：MEDIVIR AB

  公开号：US10106571B2

  公开（公告）日：2018-10-23

  The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

  本发明提供了式中化合物： 其中 B 是选自 (a) 至 (d) 组的核碱基： 和其他变量的定义、 其用途包括治疗或预防丙型肝炎病毒感染及相关方面。
• Methods of preparing ophthalmic formulations and uses of same
  申请人：Cognoptix, Inc.

  公开号：US10350309B2

  公开（公告）日：2019-07-16

  The present invention relates to a process for preparing an ointment comprising subjecting a mixture of a fluorescent molecular rotor compound, mineral oil, and grinding media to ball milling agitation and combining this mixture with a hydrophobic vehicle for an ointment. The invention also relates to an ophthalmic formulation comprising a pharmaceutically acceptable carrier and a compound of the following structural Formula (I), or a pharmaceutically acceptable salt thereof: Values and preferred values of the variables in structural Formula (I) are described herein.

  本发明涉及一种制备软膏的工艺，包括将荧光分子转子化合物、矿物油和研磨介质的混合物进行球磨搅拌，并将该混合物与软膏的疏水性载体结合。本发明还涉及一种眼科制剂，该制剂包含一种药学上可接受的载体和一种结构式（I）如下的化合物或其药学上可接受的盐： 结构式（I）中各变量的值和优选值在此描述。